Evidence map›Paper›PMID 36461624›Full record

ArticleAdvanced healthcare materials2023

A 3D Perfusable Platform for In Vitro Culture of Patient Derived Xenografts.

Lindsey K Sablatura, Kristin M Bircsak, Peter Shepherd, Madhavi Bathina, Karla Queiroz, Mary C Farach-Carson, Rick A Kittles, Pamela E Constantinou, Anthony Saleh, Nora M Navone and 1 more

Open access · greenAbstract read
In one paragraph

Article in Advanced healthcare materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Lindsey K SablaturaDepartment of BioSciences, Rice University, Houston, TX, 77005, USA.
Kristin M BircsakMIMETAS US Inc, Gaithersburg, MD, 20878, USA.
Peter ShepherdDepartment of Genitourinary Medical Oncology Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Madhavi BathinaDivision of Health Equities, Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA.
Karla QueirozMIMETAS B.V., Leiden, 2343 DH, The Netherlands.
Mary C Farach-CarsonDepartment of BioSciences, Rice University, Houston, TX, 77005, USA.
Rick A KittlesDivision of Health Equities, Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA.
Pamela E ConstantinouDepartment of BioSciences, Rice University, Houston, TX, 77005, USA.
Anthony SalehMIMETAS US Inc, Gaithersburg, MD, 20878, USA.
Nora M NavoneDepartment of Genitourinary Medical Oncology Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Daniel A HarringtonDepartment of BioSciences, Rice University, Houston, TX, 77005, USA.ORCID 0000-0003-2505-0349
Rice University · USThe University of Texas MD Anderson Cancer Center · USCity of Hope · USMDS Associates (United States) · USMimetas (Netherlands) · NL

Funding

Prostate Cancer Bone Metastasis: Biology and TargetingP01CA098912 · NCI · EMORY UNIVERSITY · PI ZAYZAFOON, MAJD · 2003 to 2019
$24.0M
NCI NIH HHS HHSN261201700015CNCI NIH HHS P01 CA098912
6 · The paper itself

Abstract

Many advanced cancer models, such as patient-derived xenografts (PDXs), offer significant benefits in their preservation of the native tumor's heterogeneity and susceptibility to treatments, but face significant barriers to use in their reliance on a rodent host for propagation and screening. PDXs remain difficult to implement in vitro, particularly in configurations that enable both detailed cellular analysis and high-throughput screening (HTS). Complex multilineage co-cultures with stromal fibroblasts, endothelium, and other cellular and structural components of the tumor microenvironment (TME) further complicate ex vivo implementation. Herein, the culture of multiple prostate cancer (PCa)-derived PDX models as 3D clusters within engineered biomimetic hydrogel matrices, in a HTS-compatible multiwell microfluidic format, alongside bone marrow-derived stromal cells and a perfused endothelial channel. Polymeric hydrogel matrices are customized for each cell type, enabling cell survival in vitro and facile imaging across all conditions. PCa PDXs demonstrate unique morphologies and reliance on TME partners, retention of known phenotype, and expected sensitivity or resistance to standard PCa therapeutics. This novel integration of technologies provides a fully human model, and expands the information to be gathered from each specimen, while avoiding the time and labor involved with animal-based testing.

Indexed as

Prostatic NeoplasmsAnimalsCoculture TechniquesDisease Models, AnimalHeterograftsHumansHydrogelsMaleProstateTumor MicroenvironmentHydrogelscancershydrogelsmicrofluidicspatient-derived xenograftsperfusion

Identifiers

PMID36461624
PMCPMC10235208
OpenAlexW4310642938

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.